Pyrazinamide
Pyrazinamide is a first-line antimycobacterial prodrug that is converted by mycobacterial pyrazinamidase to pyrazinoic acid, which disrupts the bacterial membrane potential and interferes with fatty acid biosynthesis and energy metabolism in Mycobacterium tuberculosis. It is a key component of standard short-course antituberculosis regimens, particularly valuable for its sterilizing activity against semi-dormant bacilli in acidic environments.
Molecular Weight
123.1100 g/mol
LogP
-0.60
TPSA
68.90 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
2D Structure
Cite this structure
Embed this structure
SMILES
NC(=O)c1cnccn1
InChI
InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)
Molecular Formula
C5H5N3O
HBD / HBA
1 / 3
Rotatable Bonds
1
Heavy Atoms
9
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Pyrazinamide is a first-line antimycobacterial prodrug that is converted by mycobacterial pyrazinamidase to pyrazinoic acid, which disrupts the bacterial membrane potential and interferes with fatty acid biosynthesis and energy metabolism in Mycobacterium tuberculosis. It is a key component of standard short-course antituberculosis regimens, particularly valuable for its sterilizing activity against semi-dormant bacilli in acidic environments.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Pyrazinamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL614. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 1046. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="pyrazinamide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/pyrazinamide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/pyrazinamide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/pyrazinamide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="pyrazinamide"></drugfyi-drug>